Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil in female non-obstructive CAD
NCT03010423Phase 4Terminated
- Sponsor
- Merck KGaA
- Start
- Nov 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nicorandil in coronary artery disease (CAD), sponsored by Merck KGaA. Started Nov 2016; status: terminated.
02
Drugs
nicorandil
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03010423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010423.